SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

BLSM

BlossomHill Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed4d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The FDA alignment on Phase 2 dose and planned pivotal trial for BH-30643 are key catalysts. Monitor enrollment in SOLARA-2 and any updates on accelerated approval pathway. The cash runway into Q2 2028 reduces near-term financing risk.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$14.02
T+0 close · Nov 12, 2026 · via day close
Latest settled
−2.64%
T+1 · $13.65
Vs SPY
−0.73%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $14.02entry
  2. T+1 · 20h ago −2.64%α −0.73% · $13.65
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BlossomHill Therapeutics reported Q3 2026 net loss of $24.0M ($1.29 per share), wider than the $16.0M loss in Q3 2025, driven by increased R&D spending on lead programs. The company highlighted FDA alignment on a Phase 2 dose for BH-30643 and plans for a pivotal trial, with $224.9M cash expected to fund operations into Q2 2028. Consensus estimates were not available for EPS or revenue, so no surprise or rating is assigned.

Key Financial Metrics

EPS
−$1.29

Key Facts

  • Net loss of $24.0M ($1.29 per share) for Q3 2026 vs $16.0M ($6.54 per share) in Q3 2025
  • Cash and cash equivalents of $224.9M as of September 30, 2026
  • FDA alignment on 50 mg BID as recommended Phase 2 dose for BH-30643
  • SOLARA-2 pivotal Phase 2 trial for BH-30643 in C797S-positive NSCLC expected to dose first patient in Q1 2027
  • IND filing for BH-501284 (pan-KRAS inhibitor) planned for Q1 2027
  • R&D expenses increased to $21.9M from $14.7M year-over-year
  • Completed IPO in August 2026, raising $168.3M in gross proceeds

Financial Impact

Net loss increased by $8.0M year-over-year; cash position of $224.9M provides runway into Q2 2028

net losscash and cash equivalentsR&D expenses

Risk Factors

  • Clinical-stage company with no approved products; results depend on trial outcomes
  • Net loss widening as R&D spending increases; no revenue expected in near term
  • Competition from other EGFR and KRAS inhibitors in development

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402146

Track record

19 reports on BLSM

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +37.56% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $13.65 Now $13.65 −0.00% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $14.00 Now $13.65 −2.50% settles Dec 15
  3. Nov 12, 20264d ago Press Release Neutral 4/10 Viewing Entry $14.02 Now $13.65 −2.64% settles Dec 14
  4. Sep 28, 20267w ago Press Release Bearish 7/10 Entry $21.34 to $16.39 Now $13.65 +36.04% ▲ +23.20% +23.16% vs SPY
  5. Sep 18, 20268w ago 8-K Bearish 6/10 No price data
  6. Sep 18, 20268w ago Press Release Neutral 5/10 Entry $25.74 to $13.94 Now $13.65 −46.97% ▼ −45.84% −46.05% vs SPY
  7. Sep 15, 20268w ago 8-K Neutral 3/10 Entry $22.17 to $15.48 Now $13.65 −38.43% ▼ −30.18% −33.15% vs SPY
  8. Aug 12, 202613w ago Insider Cluster Bullish 8/10 Entry $16.35 to $20.86 Now $13.65 −16.51% ▲ +27.58% +29.33% vs SPY
  9. Aug 10, 202614w ago Insider Cluster Bullish 7/10 Entry $16.52 to $22.00 Now $13.65 −17.37% ▲ +33.17% +34.23% vs SPY
  10. Aug 10, 202614w ago 8-K Neutral 4/10 Entry $16.52 to $22.00 Now $13.65 −17.37% ▲ +33.17% +34.23% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026